Google
Trusted Resources: News & Events
Latest announcements and gatherings
New Pre-transplant Treatment Regimen Improves Survival of Kids with Sickle Cell Disease, Trial Shows
A new pre-transplant conditioning regimen remarkably improves rejection rates and survival in children with sickle cell disease (SCD), according to the results of Phase 1/2 trial (NCT00920972).
The study, “Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease Following Reduced Intensity Conditioning: Results of a Phase I Trial,” appeared in the journal Biology of Blood and Marrow Transplantation.
Transplanting hematopoietic stem cells (cells that can develop into any type of blood cell) from matched sibling donors results in disease-free survival of greater than 90% in SCD patients. However, only about 18% of patients have suitable sibling donors.
Therefore, unrelated umbilical cord blood transplant (UCBT), which has been performed to treat diseases such as inherited metabolic disorders and primary immunodeficiency, became a viable alternative for patients with severe sickle cell disease and without a matched family donor.
+myBinderRelated Content
-
Higher Prevalence of Hydroxyurea Use Is Associated with Lower Hospitalization Rate in a Population of Children with ...Background: Individuals with sickle cel...
-
At 16, She’s a Pioneer in the Fight to Cure Sickle Cell DiseaseHelen Obando, a shy slip of a girl, lay ...
-
Blood TransfusionsA blood transfusion is when a donor's bl...
-
6th Annual Chicago Sickle Cell SummitDate & Time Sep 28, 2023 11:00 AM...
-
Alzheimer’s Treatment Memantine Shows Promise in Treating Sickle Cell DiseaseMemantine, a standard treatment for Alzh...
-
Family Celebrates 7-Year-Old’s Sickle Cell Cure Thanks to Sister’s Life-Saving GiftOne 7-year-old who suffered his whole li...
-
‘Natural’ Gene Mutation May Offer Way of Treating Sickle Cell Disease, Study SaysIntroducing a “natural” genetic muta...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.